July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by
